KAMADA LTD

Kamada Ltd. announced that it will release its financial results for the third quarter and nine months ended September 30, 2026, on November 9, 2026, before the market opens. The company's management will host a conference call on the same day at 8:30 AM ET to discuss the results and answer questions.

Kamada Ltd. announced record-high financial results for the first half and second quarter of 2026, demonstrating double-digit profitable growth. The company reported H1 revenues of $100.2 million and Q2 revenues of $54.9 million, while also affirming its 2026 annual guidance. Additionally, Kamada secured a significant three-year, $50 million plasma supply agreement and announced that its CFO, Chaime Orlev, will transition out of his role by year-end.

Kamada Ltd. reported record-high financial results for the second quarter and first half of 2026, driven by strong demand for its proprietary products. Second quarter revenues increased 23% year-over-year to $54.9 million, with adjusted EBITDA up 29% to $14.1 million. For the first half, revenues grew 13% to $100.2 million and adjusted EBITDA rose 14% to $25.7 million. The company also secured a new three-year, $50 million strategic plasma supply agreement and reaffirmed its full-year 2026 guidance.

Kamada Ltd. announced that its Chief Financial Officer (CFO), Chaime Orlev, will transition out of his role, effective December 31, 2026. The company has initiated a search to identify his successor. Mr. Orlev, who has served as CFO since 2017, will provide transitional support to ensure a smooth handover. Both the CEO and Mr. Orlev expressed gratitude for his contributions to the company's growth and strong financial position.

Kamada Ltd. announced it will release its financial results for the second quarter and first half ended June 30, 2026, on Wednesday, August 12, 2026, before the U.S. financial markets open. Following the release, Kamada management will host a conference call for the investment community at 8:30 AM ET to discuss the results and answer questions.

Kamada Ltd. announced it will release its financial results for the second quarter and first half ended June 30, 2026, prior to the U.S. financial markets opening on Wednesday, August 12, 2026. Following the release, Kamada management will host an investment community conference call at 8:30 AM Eastern Time to discuss the results and answer questions. Shareholders and interested parties can participate via dial-in or a live webcast.

Kamada Ltd. announced a new three-year agreement to supply normal source plasma to a leading biopharmaceutical company. This deal is projected to generate approximately $50 million in revenue over three years, with initial sales expected in the fourth quarter of 2026. The company stated that the agreement validates its investment in U.S.-based plasma collection centers and supports its vertical-integration strategy and revenue growth objectives.

Kamada Ltd. announced a three-year sales agreement to supply normal source plasma to a leading biopharmaceutical company. This agreement is expected to generate approximately $50 million in revenue over its duration, with initial commercial sales anticipated in the fourth quarter of 2026. The company stated that these expected sales are already factored into its current annual guidance, and the deal validates its investment in U.S.-based plasma collection centers, supporting its vertical integration strategy and revenue growth.

Kamada Ltd. highlighted positive results from an Investigator-Initiated Study on its product CYTOGAM® (Cytomegalovirus Immune Globulin) presented at the 2026 ISHLT Annual Meeting. The study found that CYTOGAM use was associated with improved clinical outcomes in CMV high-risk lung transplant recipients, including less activated innate immune cells and blunted lung injury in models. These findings suggest CYTOGAM's potential for immune modulation and are expected to support increased product utilization.

Kamada Ltd. highlighted positive results from an Investigator-Initiated Study on CYTOGAM® (Cytomegalovirus Immune Globulin) for solid organ transplantation, presented at the 2026 ISHLT annual meeting. The study found that CMVIG prophylaxis improved clinical outcomes and reduced activated innate immune cells in high-risk lung transplant recipients. These findings suggest CYTOGAM® may interrupt injurious innate immune responses and could shift the understanding of CMV management in lung transplants. Kamada's CEO anticipates these data will support increased product utilization.